



# INVITATION

**Wednesday 3<sup>rd</sup> March 2021**

***Heart Failure  
'What a General Practitioner  
needs to know and can do  
in 2021'***



***Speaker: Dr Shakiya Ershad  
Cardiologist, Auckland Hospital***

You are invited to attend a Novartis-Sponsored Educational Meeting

**Wednesday 3<sup>rd</sup> March 2021.**

The meeting will be held in the

**Hobson Room, Alexandra Park, Greenlane Road West, Epsom at 6.00pm**

**Agenda**

Time	Session	Speaker
6.00pm	Arrivals & Canapé and Beverage Service	
6.30pm	Presentation Begins	Dr Shakiya Ershad
7.45pm	Q&A Session	
8.00pm	Meeting Close	

Canapé and beverage service will be provided.

I hope you are able to attend this interesting, interactive and thought-provoking event.

Yours sincerely,

Ashna Siraj and Pip Acock  
Key Account Managers

[ashna.siraj@novartis.com](mailto:ashna.siraj@novartis.com) Mob 021 749 769 & [pip.acock@novartis.com](mailto:pip.acock@novartis.com) Mob 021 326 061

If you would like to attend this meeting, please return the following form to **Ashna or Pip** or fax 64 9 361 8181 before 24 February 21.



# RSVP

Please return to

[ashna.siraj@novartis.com](mailto:ashna.siraj@novartis.com), [pip.acock@novartis.com](mailto:pip.acock@novartis.com)  
or fax 64 9 361 8181  
before 24<sup>th</sup> February.

Event 3 March Alexandra Park

Doctors name/s	
Surgery name	
Email address	If circumstances change and we need to change this meeting into a virtual online meeting at short notice, it is important that we have your email address.
Phone number	
Dietary requirements	
Signature	

I have read and understood the privacy notice and hereby consent to it - please tick.



By providing your personal information to Novartis New Zealand Limited or its related bodies corporate (Novartis), you consent to Novartis collecting, storing and using your personal information in accordance with the Novartis Privacy Policy. In particular, you consent to Novartis using your personal information to communicate with you about Novartis products and/or to support your use of those products, and you consent to Novartis using your personal information for audit or inspection purposes. Novartis reserves the right to use aggregated and de-identified data collected through this activity. You also consent to Novartis using your personal information to (where applicable) invite you to, or arrange your participation in, activities managed by (or on behalf of) Novartis. Novartis is committed to patient safety. In accordance with regulatory obligations Novartis processes reports of adverse events experienced by patients taking a Novartis product, when identified by a Novartis representative (or by a third party acting on behalf of Novartis). Novartis Patient Safety may contact you or your healthcare professional in order to collect further information on the adverse event. This information may be shared with health authorities or other Pharmaceutical companies with whom Novartis has a license agreement and third parties we work with for the purpose of safety reporting. Your information may be stored on servers located in jurisdictions outside of New Zealand, such as Switzerland, United Kingdom, United States of America and others. Some of those countries may not offer the same level of privacy protection as in New Zealand. However, Novartis will enter into agreements with its third-party service providers to keep your information secure and provide adequate protection for your data. You are not obliged to provide personal information. However, if you do not provide information you may not, for example, be able to participate fully in activities managed by us. You have the right to access, update or correct your personal information and/or decline to receive communications from Novartis. To find out how, please refer to our Privacy Policy or contact our Privacy Officer at Novartis New Zealand Ltd, Mairangi Bay, Private Bag 65904 Auckland 0754, New Zealand. Phone: +64 9 361 8100 Email: [privacy.au@novartis.com](mailto:privacy.au@novartis.com).

PRESCRIPTION MEDICINE. Entresto® 24mg/26mg, 49mg/51mg, 97mg/103mg (sacubitril/valsartan) film coated tablets. Consult full Data Sheet before prescribing, for information on dosage, contraindications, precautions, interactions and adverse effects. The data sheet is available at [www.medsafe.govt.nz](http://www.medsafe.govt.nz). Entresto is a fully funded medicine under special authority – please consult [www.pharmac.govt.nz](http://www.pharmac.govt.nz). Entresto is a registered trademark of Novartis AG, Switzerland. Novartis New Zealand Limited, Auckland. Ph 0800 652 422

NZ-00760 June 2020, TAPS NA12071 BGA200610

